Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.96
+4.69 (2.28%)
AAPL  272.10
+5.92 (2.22%)
AMD  216.14
+19.54 (9.94%)
BAC  50.83
-0.24 (-0.47%)
GOOG  310.88
-0.81 (-0.26%)
META  640.38
+3.13 (0.49%)
MSFT  387.36
+2.89 (0.75%)
NVDA  193.07
+1.52 (0.80%)
ORCL  146.65
+5.34 (3.78%)
TSLA  406.25
+6.42 (1.60%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.